• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Vinca Alkaloid Calcium Folinate Extravasation Injury Cancer Chemotherapeutic Drug Proc AACR 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vnca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.PubMedCrossRefGoogle Scholar
  2. [2]
    Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.PubMedGoogle Scholar
  3. [3]
    Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.PubMedCrossRefGoogle Scholar
  4. [4]
    Gill DP, Eakin DL, Weiss GB: Cutaneous necrosis from chemotherapy in a patient with an arteriovenous fistula. Cancer Treat Rep 65: 352–353, 1981.PubMedGoogle Scholar
  5. [5]
    Dorr RT, Alberts DS, Woods MW: Vinca alkaloid ulceration: experimental mouse model and effects of local antidotes. Proc AACR 23: 109, 1982Google Scholar

Secondary literature

  1. [6]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  2. [7]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Vinblastin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 4: 42–43, 2000.Google Scholar
  3. [8]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.Google Scholar
  4. [9]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  5. [10]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  6. [11]
    Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.Google Scholar
  7. [12]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  8. [13]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  9. [14]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  10. [15]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  11. [16]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  12. [17]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 42–44, 1997.Google Scholar
  13. [18]
    Summary of product characteristics Velbe (Austria), Eli Lilly, April 1999. [19] Barth J: Paravasate und deren Behandlung. In: Barth J (ed) Zytostatika-Google Scholar
  14. [19]
    Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI - 3: 1–9, 2000.Google Scholar

Further reading

  1. Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.PubMedCrossRefGoogle Scholar
  2. Dorr RT: Extravasation of vesicant antineoplastics: clinical and experimental findings. Ariz Med 38: 271–275, 1981.PubMedGoogle Scholar
  3. Yap HJ, Blumenschein GR, Keating MJ, et al: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64: 279–283, 1980.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations